Cel Sci (CVM) Revenue (2010 - 2017)
Cel Sci (CVM) posted Revenue of $17389.0 for Q2 2017, down 86.62% sequentially from $129975.0 in Q2 2016, and down 86.62% YoY from $129975.0 in Q2 2016.
Cel Sci (CVM) Revenue (2010 - 2017) Analysis & Trends
Cel Sci has reported Revenue for 4 years, with the latest figure at $17389.0 in Q2 2017.
- Quarterly Revenue fell 86.62% year-over-year to $17389.0 in Q2 2017, while the trailing twelve-month figure through Jun 2017 was $396885.0 (down 25.51% YoY) and the FY2011 annual result came in at $956154.0, up 523.71% from the prior year.
- Revenue retreated to $17389.0 in Q2 2017 per CVM's latest filing, from $129975.0 in the prior quarter.
- Over five years, Revenue peaked at $129975.0 in Q2 2016 and troughed at $17389.0 in Q2 2017.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Revenue (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 137.11 Bn | 129.26 Bn | 2.84 Bn | 3.33 Bn |
| 2 | Regeneron Pharmaceuticals | 84.98 Bn | 76.99 Bn | 3.93 Bn | 4.29 Bn |
| 3 | Argenx Se | 64.52 Bn | 59.33 Bn | 1.37 Bn | 1.52 Bn |
| 4 | Moderna | 53.23 Bn | 48.09 Bn | 52.00 Mn | 145.00 Mn |
| 5 | BeOne Medicines | 41.23 Bn | 36.14 Bn | 1.53 Bn | 1.71 Bn |
| 6 | Alnylam Pharmaceuticals | 30.65 Bn | 27.34 Bn | 992.69 Mn | 1.29 Bn |
| 7 | Insmed | 27.15 Bn | 25.99 Bn | 358.27 Mn | 425.49 Mn |
| 8 | Royalty Pharma | 26.98 Bn | 26.14 Bn | - | 674.14 Mn |
| 9 | BioNTech SE | 26.78 Bn | 8.39 Bn | 668.28 Mn | 1.06 Bn |
| 10 | Cel Sci | 2.16 Mn | -4.37 Mn | - | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2017 | 17,389.00 |
| Jun 30, 2016 | 129,975.00 |
| Sep 30, 2011 | 172,118.00 |
| Jun 30, 2011 | 77,403.00 |
| Sep 30, 2010 | 153,300.00 |